You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: iXpressGenes, Inc. Topic: NIGMS
DESCRIPTION (provided by applicant): Crystallization, followed by subsequent structure determination, is a major step in understanding the structure- function relationship of macromolecules. Understanding macromolecule structure has become a key part in the development of new pharmaceuticals, and is a major area of NIH research. Crystallization however is also the rate limiting step, despite techn ...STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBI
Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIA
DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Allinaire Therapeutics, LLC Topic: NHLBI
Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Tfc Consultants, Inc. Topic: NIMH
DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOINVISION INC Topic: NICHD
DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Yecuris Corporation Topic: NCRR
DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: CETYA THERAPEUTICS, INC. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: LYST THERAPEUTICS LLC Topic: NHLBI
SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: FieldLine Inc. Topic: 101
Abstract During Phase Iwe will test the feasibility of developing a magnetographic camera technology as a new tool in neuroscience to facilitate the detailed analysis of electrical currents in diverse neuronal circuitsInstead of photographic imagesthe camera will produce single shot images of the magnetic fields from in vivo samples of interestsuch as a patch of the grey matter in the cerebral cor ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health